✓ Translated by DotMD AI Clinical Council Source: The lancet. Diabetes & endocrinology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40482670 ↗

Phase III Randomized Trial: Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial (N = 340)

Original Paper Title: “Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 340
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Once-weekly IcoSema achieved non-inferior HbA 1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a potentially beneficial treatment intensification option for adults with type 2 diabetes.
  • Study Design & Sample: Phase III Randomized Trial published in The lancet. Diabetes & endocrinology (N = 340 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The lancet. Diabetes & endocrinology (2025), this phase iii randomized trial evaluating 340 human participants investigated: IcoSema is a once-weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP-1 analogue) developed for the treatment of type 2 diabetes. Key clinical takeaway: Once-weekly IcoSema achieved non-inferior HbA 1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a potentially beneficial treatment intensification option for adults with type 2 diabetes.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The lancet. Diabetes & endocrinology, 2025-07-15; N = 340; Rigor 87/100): Once-weekly IcoSema achieved non-inferior HbA 1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a potentially beneficial treatment intensification option for adults with type 2 diabetes.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: multiple-vitamins-injection → Rx: insulin-aspart → Rx: insulin-aspart-szjj → Rx: glucose-and-sodium-chloride-dextrose-anhydrous-and-sodium-chloride → Condition: blood-glucose → Condition: diabetes →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40482670: Phase III Randomized Trial: Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial (N = 340)

3 of 3 Free Questions Remaining